A Phase III Clinical Trial to Evaluate the Efficacy and Safety of the Live Attenuated Varicella Vaccine

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

12,440

Participants

Timeline

Start Date

December 26, 2022

Primary Completion Date

April 14, 2024

Study Completion Date

September 14, 2026

Conditions
Varicella
Interventions
BIOLOGICAL

Investigational live attenuated varicella vaccine

0.5 ml/vial

BIOLOGICAL

Placebo of live attenuated varicella vaccine

0.5 ml/vial

Trial Locations (13)

221600

Pei County Center for Disease Control and Prevention, Xuzhou

223300

Huaiyin District Center for Disease Control and Prevention, Xuzhou

Unknown

Sinan County Center for Disease Control and Prevention, Tongren

Songtao Miao Autonomous County Center for Disease Control and Prevention, Tongren

Yuping Dong Autonomous County Center for Disease Control and Prevention, Tongren

Qi County Center for Disease Control and Prevention, Hebi

Wuzhi County Center for Disease Control and Prevention, Jiaozuo

Wuyang County Center for Disease Control and Prevention, Luohe

Mianyang Anzhou District Center for Disease Control and Prevention, Mianyang

Southern County Center for Disease Control and Prevention, Nanchong

Neijiang City Center for Disease Control and Prevention, Neijiang

Lancang Lahu Autonomous County Center for Disease Control and Prevention, Pu'er

Yanshan County Center for Disease Control and Prevention, Wenshan

All Listed Sponsors
collaborator

Beijing Institute of Biological Products Co Ltd.

INDUSTRY

collaborator

Jiangsu Province Center for Disease Control and Prevention

UNKNOWN

lead

China National Biotec Group Company Limited

INDUSTRY